Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614818 Target Snapshot

HEK293 · CELL-LINE · Homo sapiens

75,507Compounds
2,595Assays
60Approved Drugs
10,876.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats HEK293 as ChEMBL target CHEMBL614818. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
HEK293
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614818
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether HEK293 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHEK293
UniProt AccessionN/A

HEK293

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as HEK293.

Review nameHEK293
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

60
Approved
17
Phase III
10
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC508,118.0
KI4.0
EC502,754.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4794117 10.52 IC50 0.03 Preclinical
CHEMBL4800456 10.1 IC50 0.08 Preclinical
CHEMBL3822907 9.89 IC50 0.1278 Preclinical
CHEMBL15177 9.8 IC50 0.16 Preclinical
CHEMBL4094083 9.77 IC50 0.17 Preclinical
CHEMBL4075161 9.64 IC50 0.23 Preclinical
CHEMBL4066549 9.62 IC50 0.242 Preclinical
CHEMBL139702 9.55 IC50 0.28 Preclinical
CHEMBL3823024 9.51 IC50 0.3065 Preclinical
CHEMBL469912 9.46 IC50 0.35 Clinical
Distribution

pChEMBL Value Distribution

1384
5.0
554
5.5
300
6.0
137
6.5
118
7.0
105
7.5
83
8.0
35
8.5
15
9.0
11
9.5
pChEMBL
Approved Drugs

Approved Drugs

DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
TALAZOPARIB
CHEMBL3137320
Approved 2018
PANOBINOSTAT
CHEMBL483254
Approved 2015
CABOZANTINIB
CHEMBL2105717
Approved 2012
NILOTINIB
CHEMBL255863
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
GEMCITABINE
CHEMBL888
Approved 1996
DOCETAXEL ANHYDROUS
CHEMBL92
Approved 1995
DOCETAXEL
CHEMBL3545252
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
PACLITAXEL
CHEMBL428647
Approved 1992
PODOFILOX
CHEMBL61
Approved 1990
MITOXANTRONE
CHEMBL58
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
NICLOSAMIDE
CHEMBL1448
Approved 1982
CALCITONIN SALMON
CHEMBL3989767
Approved 1978
DOXORUBICIN
CHEMBL53463
Approved 1974
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
MAZINDOL
CHEMBL781
Approved 1973
VINBLASTINE
CHEMBL159
Approved 1965
VINCRISTINE
CHEMBL90555
Approved 1963
COLCHICINE
CHEMBL107
Approved 1961
METHOTREXATE
CHEMBL34259
Approved 1953
MERCAPTOPURINE ANHYDROUS
CHEMBL1425
Approved 1953
PYRIMETHAMINE
CHEMBL36
Approved 1953
CHLOROQUINE
CHEMBL76
Approved 1949
Assay Landscape

Assay Landscape

2,596
Total Assays
1,893
Tested Compounds
5
Assay Types
ADME — 1,251 assays, 1,893 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1,251 1,893 5.2
Functional — 868 assays, 1,490 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 864 1,490 5.4
organism-based format 4 0
Toxicity — 454 assays, 381 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 454 381 5.1
Binding — 15 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 15 35 5.8
Unassigned — 8 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine